The differential impact of p16INK4a or p19ARF deficiency on cell growth and tumorigenesis
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Mounting genetic evidence suggests that each product of the Ink4a/Arf locus, p16(INK4a) and p19(ARF), possesses tumor-suppressor activity (Kamijo et al., 1997; Krimpenfort et al., 2001; Sharpless et al., 2001a). We report the generation and characterization of a p19(ARF)-specific knockout allele (p19(ARF)-/-) and direct comparison with mice and derivative cells deficient for p16(INK4a), both p16(INK4a) and p19(ARF), and p53. Like Ink4a/Arf-/- murine embryo fibroblasts (MEFs), p19(ARF)-/- MEFs were highly susceptible to oncogenic transformation, exhibited enhanced subcloning efficiency at low density, and resisted both RAS- and culture-induced growth arrest. In contrast, the biological profile of p16(INK4a)-/- MEFs in these assays more closely resembled that of wild-type cells. In vivo, however, both p19(ARF)-/- and p16(INK4a)-/- animals were significantly more tumor prone than wild-type animals, but each less so than p53-/- or Ink4a/Arf-/- animals, and with differing tumor spectra. These data confirm the predominant role of p19(ARF) over p16(INK4a) in cell culture-based assays of MEFs, yet also underscore the importance of the analysis of tumor suppressors across many cell types within the organism. The cancer-prone conditions of mice singly deficient for either p16(INK4a) or p19(ARF) agree with data derived from human cancer genetics, and reinforce the view that both gene products play significant and nonredundant roles in suppressing malignant transformation in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CDKN2A mRNA levels are regulated by transcription and mRNA stability104,111.”
From Guidelines for minimal information on cellular senescence experimentation in vivo (2024) · cites this paper as [104]
In the citing paper
“Traditionally, these models contain luminescent or fluorescent reporter systems yielding increased signal dependent upon the expression level of p21 or p168,83,104–107.”
From Guidelines for minimal information on cellular senescence experimentation in vivo (2024) · cites this paper as [104]
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“Likewise, RAS-induced growth arrest requires p16INK4a–Rb in human cells (and not ARF), while the opposite appears true in MEFs (Kamijo et al., 1997; Serrano et al., 1997; Zhu et al., 1998; Krimpenfort et al., 2001; Sharpless et al., 2001a; Wei et al., 2001; Brookes et al., 2002; Huot et al., 2002).”
BackgroundA cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751 · cited 1×
“Human genetic data suggest that both Ink4a/Arf products are important tumor-suppressor proteins (Hussussian et al., 1994; Kamb et al., 1994; FitzGerald et al., 1996; Randerson-Moor et al., 2001; Rizos et al., 2001; Hewitt et al., 2002).”
BackgroundRole of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 4×
“90% 9% Ink4a/Arf / Not determined, comparable colony followed by Serrano et al. (1996) As cohorts were not followed for equal lengths of time, the tumor incidences are shown as the percentage of the total number of tumors analysed.”
BackgroundInfluentialSelf-citationTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“Even in the unlikely event that this transcript is translated, however, previous results suggest that such a small fragment of p19ARF could not bind mdm2, could not stabilize p53, and would not cause growth arrest in cells (Pomerantz et al., 1998; Weber et al., 2000; Korgaonkar et al., 2002).”
ResultSelf-citationKiyono, T., Foster, S. A., Koop, J. I., McDougall, J. K., Galloway, D. A., & Klingelhutz, A. J. (1998) · Nature · doi:10.1038/23962 · Cited by 1,206 · cited 2×
“…accumulates in serially passaged primary human cells, and immortalization of these cells requires p16INK4a loss, generally through promoter methylation (Brenner et al., 1998; Foster et al., 1998; Huschtscha et al., 1998; Kiyono et al., 1998; Rheinwald et al., 2002; Sviderskaya et al., 2003).”
BackgroundEfficient in vivo manipulation of mouse genomic sequences at the zygote stage.
Lakso, M., Pichel, J. G., Gorman, J. R., Sauer, B., Okamoto, Y., Lee, E., Alt, F. W., & Westphal, H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5860 · Cited by 1,125 · cited 1×
“High-percentage chimeras were then crossed to a Cre-deletor strain (EIIa-CRE; Lakso et al., 1996) to remove the selection cassette, and correct excision was confirmed by Southern (not shown), PCR (Figure 1c) and direct sequencing of the targeted allele.”
MethodGermline p16 mutations in familial melanoma
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., & Dracopoli, N. C. (1994) · Nature Genetics · doi:10.1038/ng0994-15 · Cited by 977 · cited 1×
“Human genetic data suggest that both Ink4a/Arf products are important tumor-suppressor proteins (Hussussian et al., 1994; Kamb et al., 1994; FitzGerald et al., 1996; Randerson-Moor et al., 2001; Rizos et al., 2001; Hewitt et al., 2002).”
BackgroundLoss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
Sharpless, N. E., Bardeesy, N., Lee, K.-H., Carrasco, D., Castrillon, D. H., Aguirre, A. J., Wu, E. A., Horner, J. W., & DePinho, R. A. (2001) · Nature · doi:10.1038/35092592 · Cited by 848 · cited 21×
“…indicated Oncogene were larger (7.8 versus 28.7mm2, P¼ 0.04) and more likely to cause morbidity (e.g. tachypnea, hemothorax) than in wild-type littermate animals; the number of tumor nodules seen in p19ARF / was not significantly increased, in contrast to p16INK4a / mice (Sharpless et al., 2001a).”
BackgroundMethodResultInfluentialSelf-citationSenescence of human fibroblasts induced by oncogenic Raf
Zhu, J., Woods, D., McMahon, M., & Bishop, J. M. (1998) · Genes & Development · doi:10.1101/gad.12.19.2997 · Cited by 826 · cited 2×
“Likewise, RAS-induced growth arrest requires p16INK4a–Rb in human cells (and not ARF), while the opposite appears true in MEFs (Kamijo et al., 1997; Serrano et al., 1997; Zhu et al., 1998; Krimpenfort et al., 2001; Sharpless et al., 2001a; Wei et al., 2001; Brookes et al., 2002; Huot et al., 2002).”
BackgroundSherr, C. J., & DePinho, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)00046-5 · Cited by 745 · cited 1×
“It appears, however, that a somewhat generic feature(s) of cell culture (‘oncogenic stress’) is capable of inducing both p16INK4a and ARF expression in a multitude of cell types (Sherr and DePinho, 2000).”
BackgroundSelf-citationTumor suppression by Ink4a-Arf: progress and puzzles.
Lowe, S. W., & Sherr, C. J. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00013-8 · Cited by 699 · cited 1×
“The Ink4a/Arf locus encodes two proteins, p16INK4a and p14ARF (p19ARF in the mouse), in overlapping reading frames which are commonly codeleted in a large variety of human cancers (reviewed in Lowe and Sherr 2003).”
BackgroundEpidermal growth factor receptor and Ink4a/Arf
Bachoo, R. M., Maher, E. A., Ligon, K. L., Sharpless, N. E., Chan, S. S., You, M. J., Tang, Y., DeFrances, J., Stover, E., Weissleder, R., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00046-6 · Cited by 652 · cited 4×
“A compilation of results obtained from p16INK4a / , p19ARF / , Ink4a/Arf / , p53 / , and p16INK4a/p53 compound null mice and cells is shown in Table 2 (present data; (Sharpless et al., 2001a, b, 2002, 2003; Bachoo et al., 2002; Kannan et al., 2003).”
BackgroundMethodInfluentialSelf-citationZindy, F., Quelle, D. E., Roussel, M. F., & Sherr, C. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201178 · Cited by 574 · cited 1×
“A likely explanation for this observation is that even at early passage, MEFs highly express the other INK4-class regulators p18INK4c and p19INK4d (Zindy et al., 1997).”
BackgroundLoss of p16Ink4a confers susceptibility to metastatic melanoma in mice
Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A., & Berns, A. (2001) · Nature · doi:10.1038/35092584 · Cited by 568 · cited 8×
“…encoded by the Ink4a/Arf locus encodes tumor-suppressor activity appears definitively resolved by the collective experimental evidence of this report and others (Kamijo et al., 1997, 1999; Krimpenfort et al., 2001; Sharpless et al., 2001a, 2002, 2003; Bachoo et al., 2002; Kannan et al., 2003).”
BackgroundResultInfluentialRheinwald, J. G., Hahn, W. C., Ramsey, M. R., Wu, J. Y., Guo, Z., Tsao, H., De Luca, M., Catricalà, C., & O'Toole, K. M. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.14.5157-5172.2002 · Cited by 338 · cited 4×
“…accumulates in serially passaged primary human cells, and immortalization of these cells requires p16INK4a loss, generally through promoter methylation (Brenner et al., 1998; Foster et al., 1998; Huschtscha et al., 1998; Kiyono et al., 1998; Rheinwald et al., 2002; Sviderskaya et al., 2003).”
BackgroundMethodInfluentialConstitutive telomerase expression promotes mammary carcinomas in aging mice
Artandi, S. E., Alson, S., Tietze, M. K., Sharpless, N. E., Ye, S., Greenberg, R. A., Castrillon, D. H., Horner, J. W., Weiler, S. R., Carrasco, R. D., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.112515399 · Cited by 317 · cited 2×
“For example, four of 41 p19ARF / mice survived 480 weeks, whereas Ink4a/ Arf / mice in this background seldom survive over a year (Figure 3a; Artandi et al., 2002; Sharpless et al., 2001b).”
BackgroundSelf-citationA germline deletion of p14ARF but not CDKN2A in a melanoma-neural system tumour syndrome family
Randerson-Moor, J. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.1.55 · Cited by 281 · cited 1×
“Human genetic data suggest that both Ink4a/Arf products are important tumor-suppressor proteins (Hussussian et al., 1994; Kamb et al., 1994; FitzGerald et al., 1996; Randerson-Moor et al., 2001; Rizos et al., 2001; Hewitt et al., 2002).”
BackgroundCooperative Signals Governing ARF-Mdm2 Interaction and Nucleolar Localization of the Complex
Weber, J. D., Kuo, M.-L., Bothner, B., DiGiammarino, E. L., Kriwacki, R. W., Roussel, M. F., & Sherr, C. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.7.2517-2528.2000 · Cited by 275 · cited 1×
“Even in the unlikely event that this transcript is translated, however, previous results suggest that such a small fragment of p19ARF could not bind mdm2, could not stabilize p53, and would not cause growth arrest in cells (Pomerantz et al., 1998; Weber et al., 2000; Korgaonkar et al., 2002).”
ResultBrenner, A. J., Stampfer, M. R., & Aldaz, C. M. (1998) · Oncogene · doi:10.1038/sj.onc.1201919 · Cited by 272 · cited 2×
“…accumulates in serially passaged primary human cells, and immortalization of these cells requires p16INK4a loss, generally through promoter methylation (Brenner et al., 1998; Foster et al., 1998; Huschtscha et al., 1998; Kiyono et al., 1998; Rheinwald et al., 2002; Sviderskaya et al., 2003).”
BackgroundInactivation of p16 in Human Mammary Epithelial Cells by CpG Island Methylation
Foster, S. A., Wong, D. J., Barrett, M. T., & Galloway, D. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.4.1793 · Cited by 229 · cited 2×
“…accumulates in serially passaged primary human cells, and immortalization of these cells requires p16INK4a loss, generally through promoter methylation (Brenner et al., 1998; Foster et al., 1998; Huschtscha et al., 1998; Kiyono et al., 1998; Rheinwald et al., 2002; Sviderskaya et al., 2003).”
BackgroundINK4a‐deficient human diploid fibroblasts are resistant to RAS‐induced senescence
Brookes, S., Rowe, J., Ruas, M., Llanos, S., Clark, P. A., Lomax, M., James, M. C., Vatcheva, R., Bates, S., Vousden, K. H., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf289 · Cited by 220 · cited 1×
“Likewise, RAS-induced growth arrest requires p16INK4a–Rb in human cells (and not ARF), while the opposite appears true in MEFs (Kamijo et al., 1997; Serrano et al., 1997; Zhu et al., 1998; Krimpenfort et al., 2001; Sharpless et al., 2001a; Wei et al., 2001; Brookes et al., 2002; Huot et al., 2002).”
BackgroundRole of p14ARF in Replicative and Induced Senescence of Human Fibroblasts
Wei, W., Hemmer, R. M., & Sedivy, J. M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.20.6748-6757.2001 · Cited by 217 · cited 3×
“Likewise, RAS-induced growth arrest requires p16INK4a–Rb in human cells (and not ARF), while the opposite appears true in MEFs (Kamijo et al., 1997; Serrano et al., 1997; Zhu et al., 1998; Krimpenfort et al., 2001; Sharpless et al., 2001a; Wei et al., 2001; Brookes et al., 2002; Huot et al., 2002).”
BackgroundOncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation
Lin, A. W., & Lowe, S. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091100298 · Cited by 215 · cited 1×
“Cells from this p19ARF / strain, however, demonstrate normal p16INK4a expression at early passage compared to littermate p19ARFþ /þ animals, while cells from the previously described strain demonstrate a several-fold increase in p16INK4a expression (Kamijo et al., 1997; Lin and Lowe, 2001).”
FitzGerald, M. G., Harkin, D. P., Silva-Arrieta, S., MacDonald, D. J., Lucchina, L. C., Unsal, H., O'Neill, E., Koh, J., Finkelstein, D. M., Isselbacher, K. J., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8541 · Cited by 200 · cited 1×
“Human genetic data suggest that both Ink4a/Arf products are important tumor-suppressor proteins (Hussussian et al., 1994; Kamb et al., 1994; FitzGerald et al., 1996; Randerson-Moor et al., 2001; Rizos et al., 2001; Hewitt et al., 2002).”
BackgroundSharpless, N. E., Ferguson, D. O., O'Hagan, R. C., Castrillon, D. H., Lee, C., Farazi, P. A., Alson, S., Fleming, J., Morton, C. C., Frank, K., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00425-7 · Cited by 175 · cited 21×
“…indicated Oncogene were larger (7.8 versus 28.7mm2, P¼ 0.04) and more likely to cause morbidity (e.g. tachypnea, hemothorax) than in wild-type littermate animals; the number of tumor nodules seen in p19ARF / was not significantly increased, in contrast to p16INK4a / mice (Sharpless et al., 2001a).”
BackgroundMethodResultInfluentialSelf-citationA melanoma-associated germline mutation in exon 1β inactivates p14ARF
Rizos, H., Puig, S., Badenas, C., Malvehy, J., Darmanian, A. P., Jiménez, L., Milà, M., & Kefford, R. F. (2001) · Oncogene · doi:10.1038/sj.onc.1204728 · Cited by 171 · cited 1×
“Human genetic data suggest that both Ink4a/Arf products are important tumor-suppressor proteins (Hussussian et al., 1994; Kamb et al., 1994; FitzGerald et al., 1996; Randerson-Moor et al., 2001; Rizos et al., 2001; Hewitt et al., 2002).”
BackgroundDual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas
Bardeesy, N., Bastian, B. C., Hezel, A., Pinkel, D., DePinho, R. A., & Chin, L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.6.2144-2153.2001 · Cited by 166
Self-citationGermline mutation of ARF in a melanoma kindred
Hewitt, C. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.11.1273 · Cited by 132 · cited 1×
“Human genetic data suggest that both Ink4a/Arf products are important tumor-suppressor proteins (Hussussian et al., 1994; Kamb et al., 1994; FitzGerald et al., 1996; Randerson-Moor et al., 2001; Rizos et al., 2001; Hewitt et al., 2002).”
BackgroundSviderskaya, E. V., Gray-Schopfer, V. C., Hill, S. P., Smit, N. P., Evans-Whipp, T. J., Bond, J., Hill, L., Bataille, V., Peters, G., Kipling, D., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.10.723 · Cited by 123 · cited 1×
“…accumulates in serially passaged primary human cells, and immortalization of these cells requires p16INK4a loss, generally through promoter methylation (Brenner et al., 1998; Foster et al., 1998; Huschtscha et al., 1998; Kiyono et al., 1998; Rheinwald et al., 2002; Sviderskaya et al., 2003).”
BackgroundComponents of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model
Kannan, K., Sharpless, N. E., Xu, J., O'Hagan, R. C., Bosenberg, M., & Chin, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0336397100 · Cited by 116 · cited 2×
“A compilation of results obtained from p16INK4a / , p19ARF / , Ink4a/Arf / , p53 / , and p16INK4a/p53 compound null mice and cells is shown in Table 2 (present data; (Sharpless et al., 2001a, b, 2002, 2003; Bachoo et al., 2002; Kannan et al., 2003).”
BackgroundMethodSelf-citationARF Function Does Not Require p53 Stabilization or Mdm2 Relocalization
Korgaonkar, C., Zhao, L., Modestou, M., & Quelle, D. E. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.1.196-206.2002 · Cited by 110 · cited 1×
“Even in the unlikely event that this transcript is translated, however, previous results suggest that such a small fragment of p19ARF could not bind mdm2, could not stabilize p53, and would not cause growth arrest in cells (Pomerantz et al., 1998; Weber et al., 2000; Korgaonkar et al., 2002).”
ResultRandle, D. H., Zindy, F., Sherr, C. J., & Roussel, M. F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171217498 · Cited by 109 · cited 2×
“In murine cells, p16INK4a appears to participate in culture-induced arrest of a few cell types (e.g. astrocytes (Bachoo et al., 2002), macrophages (Randle et al., 2001), and v-abl transduced lymphocytes (Sachs et al., in submission)), but p19ARF appears more important in most of these cases.”
BackgroundHuot, T. J., Rowe, J., Harland, M., Drayton, S., Brookes, S., Gooptu, C., Purkis, P., Fried, M., Bataille, V., Hara, E., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.23.8135-8143.2002 · Cited by 107 · cited 1×
“Likewise, RAS-induced growth arrest requires p16INK4a–Rb in human cells (and not ARF), while the opposite appears true in MEFs (Kamijo et al., 1997; Serrano et al., 1997; Zhu et al., 1998; Krimpenfort et al., 2001; Sharpless et al., 2001a; Wei et al., 2001; Brookes et al., 2002; Huot et al., 2002).”
BackgroundTolbert, D., Lu, X., Yin, C., Tantama, M., & Van Dyke, T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.1.370-377.2002 · Cited by 85 · cited 1×
“Several groups (Kamijo et al., 1997, 1999; Eischen et al., 2002; Tolbert et al., 2002) have reported following cohorts of the p19ARF CS mice for spontaneous tumors; all report median tumor latencies in the 27–49 week range, whereas the strain reported in this series appears to develop tumors B10–30…”
BackgroundSherr, C. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00486-x · Cited by 78
Research works printed but not linked: 2
- Festing M . (1998). Mouse Genome Informatics Web Site. Vol. 2001 The Jackson Laboratory: Bar Harbor, Maine.
- Sharpless NE, Kannan K, Xu J, Bosenberg M and Chin L . (2003). Oncogene. (in press).
Cited by
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Miller, A. J., & Mihm, M. C. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052166 · Cited by 1,339
Senescent cells: an emerging target for diseases of ageing
Childs, B. G., Gluscevic, M., Baker, D. J., Laberge, R.-M., Marquess, D., Dananberg, J., & van Deursen, J. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.116 · Cited by 1,284
LKB1 modulates lung cancer differentiation and metastasis
Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., et al. (2007) · Nature · doi:10.1038/nature06030 · Cited by 1,064
Self-citationThe signals and pathways activating cellular senescence
Ben-Porath, I., & Weinberg, R. A. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.10.013 · Cited by 1,046
Metadata
- Authors
- Sharpless, N. E., Ramsey, M. R., Balasubramanian, P., Castrillon, D. H., & DePinho, R. A.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Harvard University (US)
- Corresponding author
- Sharpless, Norman E
- Venue
- Oncogene
- Published
- 2004-01-15
- Volume
- 23
- Issue
- 2
- Pages
- 379-385
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2084912361
- Cited by
- 224
- References
- 36
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 4 · 2023: 10 · 2022: 11 · 2021: 6 · 2020: 5 · 2019: 10 · 2018: 5 · 2017: 8 · 2016: 9 · 2015: 6 · 2014: 9 · 2013: 7 · 2012: 14
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- American Cancer Society
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- p16INK4a, p19ARF, INK4a/ARF locus, tumor suppressor, p53, knockout mice, mouse embryonic fibroblasts, oncogenic transformation, subclonal expansion, cancer susceptibility
- MeSH terms
- Alleles, Animals, Cell Division, Cell Transformation, Neoplastic, Cells, Cultured, Embryo, Mammalian, Fibroblasts, Genotype, Neoplasms, Phenotype, Tumor Suppressor Protein p53, Gene Deletion, Cyclin-Dependent Kinase Inhibitor p16, Tumor Suppressor Protein p14ARF, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.